Webinars & Events

Ask the PIs

Ask the PIs Networking Event

Thursday, 3 December, from 18:00 – 19:15 CST - See in your time zone.

This small-group, interactive event gives trainees and postdocs a unique chance to explore career transitions, gain practical insights from experts, and build meaningful professional connections.

A similar format to the NIC's popular Meet the Experts mixer, the event will consist of three rounds of breakout sessions, where you'll get to meet and engage with multiple Principal Investigators for personalized conversations and insights on navigating your path to independence. Don't miss this chance to advance your career and form new connections! 

Trainees and postdocs can now register below.

Register Now

Meet Our Participating Faculty

Charley de Bock, BSc, MSc, PhD - Australia

Associate Professor, Head of the Functional Genomics of Leukaemia Group
Children's Cancer Institute

Associate Professor Charles de Bock is Head of the Functional Genomics of Leukaemia Group at the Children's Cancer Institute in Sydney, Australia. His research seeks to understand how genetic and epigenetic alterations drive acute lymphoblastic leukaemia and to translate these discoveries into new targeted therapies. His laboratory develops advanced mouse models and utilises a biobank of more than 130 molecularly characterised patient-derived xenograft models to study disease biology and evaluate novel treatments for high-risk childhood leukaemias. He is also actively involved in the Australian ZERO Childhood Cancer Program, a national precision medicine initiative that provides comprehensive genomic profiling for children diagnosed with cancer throughout Australia.

Elsa Bernard

Roi Gazit, PhD - Israel

Group Leader, Computational Clinical Oncology Group
Gustave Roussy

Learn More

Elsa Bernard joined Gustave Roussy in 2024 to lead the Computational Clinical Oncology Laboratory. Previously, she worked at the Francis Crick Institute (London, UK) from 2021 to 2023 in Charles Swanton’s laboratory and at Memorial Sloan Kettering Cancer Center (New York, USA) from 2016 to 2021 in Elli Papaemmanuil’s laboratory. She obtained her PhD in computational biology from Institut Curie (Paris, France) in 2016. Her research broadly focuses on translating computational genomics to precision cancer medicine, with a particular interest in myeloid malignancies and the evolution of precursor conditions such as clonal hematopoiesis.

Antonio Morales-Hernández

Lev Kats, PhD - Australia

Laboratory Head, Cancer Biology and Therapeutics Program
Peter MacCallum Cancer Center

A/Prof Lev Kats is a laboratory head in the Cancer Biology and Therapeutics Program at the Peter MacCallum Cancer Centre in Melbourne, Australia. He is also the co-theme leader of Myeloma Medicines in the Barrie Dalgleish Centre for Myeloma & Related Blood Cancers and a Blood Cancer United Scholar. He completed his undergraduate and PhD studies at Monash University and postdoctoral training at Beth Israel Deaconess Medical Center/Harvard Medical School. He started his independent laboratory in 2016 with a focus on targeted therapies, epigenetics and haematological malignancies.  

Vanessa Scanlon

Gemma Kelly, PhD - Australia

Laboratory Head and Co-Lead of the Cancer Division
WEHI

Professor Gemma Kelly is an NHMRC Leadership Fellow, Laboratory Head and Co-Lead of the Cancer Division at WEHI. She carried out her undergraduate and PhD studies in the UK and relocated to Australia in 2009 following the award of a Kay Kendall Leukemia Fund Fellowship. In 2019 she started her own lab in the Blood Cells and Blood Cancer Division at WEHI. Gemma’s team are focused on improving outcomes for blood cancer patients by targeting the intrinsic apoptotic pathway. They use novel preclinical cancer models and sophisticated genetic screening to identify resistance factors to cancer therapy and identify new therapeutic regimens that can induce deeper responses.

Julia Tilburg

Dirk Loeffler, PhD - USA

Assistant Member, Department of Hematology
St. Jude Children's Research Hospital

Dirk Loeffler, PhD, is an Assistant Member in the Department of Hematology at St. Jude Children’s Research Hospital, where he leads the Loeffler lab. His research focuses on hematopoietic stem cell biology, with particular emphasis on cell polarity and asymmetric cell division, clonal hematopoiesis, and inherited mutations that predispose to blood disorders, such as germline RUNX1 variants in Familial Platelet Disorder with associated Myeloid Malignancy. His lab combines long-term live-cell imaging, single-cell tracking, and custom computational tools to follow stem cell behavior and fate decisions over time. Before joining St. Jude, he trained at the Helmholtz Center in Munich, Germany, and at ETH Zurich in Switzerland.

Jenny Hansson

Craig Morrell, DVM, PhD - USA

Co-Director of the Aab Cardiovascular Research Institute
University of Rochester

Dr. Morrell earned his undergraduate degree from Brown University in 1995. He then graduated from Tufts University School of Veterinary Medicine in 2000 before beginning a comparative pathology fellowship at The Johns Hopkins University School of Medicine while concurrently completing a PhD in Pathobiology in 2005.  He has been at the University of Rochester since 2009 and is Co-Director of the Aab Cardiovascular Research Institute. His research interests include studies of platelets as immune mediators and the intersection between hematopoiesis/megakaryopoiesis and thrombo-inflammation.

Jenny Hansson

Shalin Naik, PhD - Australia

Lab Head
WEHI

Prof Naik is a graduate of the University of QLD, did his PhD at WEHI, and his postdoc at the Netherlands Cancer Institute. Since 2014, Prof Naik has been a Laboratory Head in the Immunology Division where his lab creates novel technologies and applies these using single cell and clonal systems biology. Prof Naik has made major contributions to haematopoiesis, immunology and cancer using these approaches. This has in turn led to several translational endeavours including next-generation Dendritic Cell Immunotherapy, and the correction of blood and immune disorders through stem cell editing and engineering.

Jenny Hansson

Eric Pietras, PhD - USA

Assistant Professor, CCA - Cancer biology and Immunology
Amsterdam UMC

Learn More

Dr Rachel Thijssen is an Assistant Professor at the Amsterdam UMC, the Netherlands and is an expert in targeted therapy resistance in blood cancer. Supported by an ERC StG, an EHA Advanced Research Grant and a NWO VIDI Grant, her group focuses on unravelling how haematopoietic cancer cells evade cell death, with a focus on venetoclax resistance in leukaemias using state-of-the-art techniques such as single-cell multiome (RNA+ATAC) sequencing and single-cell long-read sequencing (Nanopore).

Jenny Hansson

Louise Purton, PhD - Australia

Head, Stem Cell Regulation
St. Vincent's Institute

Professor Louise Purton has trained in three countries. Her independent research contributions include the discovery that vitamin A is a major regulator of blood cell production and that vitamin A enhances blood-forming stem cell self-renewal. Her senior author Cell research was the first to identify novel roles for bone marrow microenvironment cells in regulating blood cell diseases. Louise received the 2022 ISEH McCulloch and Till Award and in 2023 she was awarded the ISEH Inclusive Leadership Award. She is a bilateral cochlear implant recipient and is currently the President of ISEH.

Jenny Hansson

Anastasia Tikhonova, PhD - Canada

Senior Scientist
Princess Margaret Cancer Centre, UHN

Dr. Anastasia Tikhonova, PhD, is a Senior Scientist at the Princess Margaret Cancer Centre, University Health Network, and an Assistant Professor in the Department of Medical Biophysics at the University of Toronto. She holds a Tier 2 Canada Research Chair in Stem Cell Niche Biology. In 2020, Dr. Tikhonova established her independent research program at the Princess Margaret Cancer Centre. Her laboratory investigates the reciprocal interactions between hematopoietic cells and their microenvironment in normal hematopoiesis, premalignant conditions, and hematologic malignancies, with the goal of identifying mechanisms of disease progression and novel therapeutic opportunities.

David Traver, PhD - USA

Director, Center for Developmental and Regenerative Biology
Cedars-Sinai Guerin Children’s

The Traver laboratory studies the formation and function of hematopoietic stem cells in the early embryo, and how the progeny of these cells provide immunity to the developing animal.  Through direct imaging approaches in the zebrafish embryo, the Traver laboratory demonstrated that HSCs derive from the transdifferentiation of hemogenic endothelium comprising the aortic floor.  A major goal is to understand the genetic hierarchies that regulate this event.  Over the past few years, the Traver group has demonstrated that a variety of signals from the somite are required to instruct HSC fate during the early migration of their shared vascular precursors.  Dr. Traver has received a Career Development Award from the National Institutes of Health, a New Faculty Award from the California Institute for Regenerative Medicine, and Scholar Awards from the March of Dimes Foundation, the American Society of Hematology, the Sidney Kimmel Foundation for Cancer Research, and the Leukemia and Lymphoma Society.  Most recently, he was presented the Till & McCulloch Award by the International Society for Experimental Hematology. 

Jenny Hansson

Pamela Wenzel, PhD - USA

Professor of Integrative Biology & Pharmacology
University of Texas Health Science Center

Pamela Wenzel, Ph.D., is a Professor of Integrative Biology & Pharmacology at the McGovern Medical School, University of Texas Health Science Center at Houston. Dr. Wenzel has the honor of being one of a few two-time awardees of the American Hematology Society Scholar Award. In her postdoctoral fellowship at Children’s Hospital Boston, she studied a concept novel to the field of hematology, demonstrating that force generated by blood flow promotes blood cell development. Following her recruitment to Texas, Dr. Wenzel continued to distinguish herself as an authority in mechanobiology, showing that force regulates the emergence of the first stem cells that populate the adult blood system. She has produced a body of research on the hematopoietic niche, but has also shown that cancer cells can use force to hijack the lymphatic system for metastasis throughout the body. And, based on her discovery that biomechanical cues contribute to immunomodulatory activities of bone marrow stromal cells, she has worked with clinicians to patent and license intellectual property for a stem cell therapy for the treatment of traumatic brain injury. Dr. Wenzel’s most recent research focuses on how mitochondrial bioenergetics are regulated by flow in development of the blood system.